CRLF2 and leukemia: We next sought to determine whether Eμ-Crlf2/Jak2R683G leukemias with sustained knockdown of Jak2 (referred to here as “Jak2 knockdown-persistent cells”) obtained from moribund Dox-treated recipient mice (Fig. 3F) maintained an ability to respond to mutant Jak2.